Dual targeting of FGFR3 and ERBB3 enhances the efficacy of FGFR inhibitors in FGFR3 fusion-driven bladder cancer

BACKGROUND: Mutations and fusions in Fibroblast Growth Factor Receptor 3 (FGFR3) occur in 10–20% of metastatic urothelial carcinomas and confer sensitivity to FGFR inhibitors. However, responses to these agents are often short-lived due to the development of acquired resistance. The objective of thi...

Descripción completa

Detalles Bibliográficos
Autores principales: Weickhardt, Andrew J., Lau, David K., Hodgson-Garms, Margeaux, Lavis, Austen, Jenkins, Laura J., Vukelic, Natalia, Ioannidis, Paul, Luk, Ian Y., Mariadason, John M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9063072/
https://www.ncbi.nlm.nih.gov/pubmed/35501832
http://dx.doi.org/10.1186/s12885-022-09478-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9063072/
https://www.ncbi.nlm.nih.gov/pubmed/35501832
http://dx.doi.org/10.1186/s12885-022-09478-4

Ejemplares similares